{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T18:28:42Z","timestamp":1776018522673,"version":"3.50.1"},"reference-count":145,"publisher":"Oxford University Press (OUP)","issue":"16","license":[{"start":{"date-parts":[[2018,3,9]],"date-time":"2018-03-09T00:00:00Z","timestamp":1520553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/about_us\/legal\/notices"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 DK089167"],"award-info":[{"award-number":["R01 DK089167"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R42 GM087013"],"award-info":[{"award-number":["R42 GM087013"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["DBI-0965741"],"award-info":[{"award-number":["DBI-0965741"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Robert J. Sokol, MD, Endowed Chair in Systems Biology"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Motivation<\/jats:title>\n                    <jats:p>Identification of novel therapeutic effects for existing US Food and Drug Administration (FDA)-approved drugs, drug repurposing, is an approach aimed to dramatically shorten the drug discovery process, which is costly, slow and risky. Several computational approaches use transcriptional data to find potential repurposing candidates. The main hypothesis of such approaches is that if gene expression signature of a particular drug is opposite to the gene expression signature of a disease, that drug may have a potential therapeutic effect on the disease. However, this may not be optimal since it fails to consider the different roles of genes and their dependencies at the system level.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We propose a systems biology approach to discover novel therapeutic roles for established drugs that addresses some of the issues in the current approaches. To do so, we use publicly available drug and disease data to build a drug-disease network by considering all interactions between drug targets and disease-related genes in the context of all known signaling pathways. This network is integrated with gene-expression measurements to identify drugs with new desired therapeutic effects based on a system-level analysis method. We compare the proposed approach with the drug repurposing approach proposed by Sirota et al. on four human diseases: idiopathic pulmonary fibrosis, non-small cell lung cancer, prostate cancer and breast cancer. We evaluate the proposed approach based on its ability to re-discover drugs that are already FDA-approved for a given disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Availability and implementation<\/jats:title>\n                    <jats:p>The R package DrugDiseaseNet is under review for publication in Bioconductor and is available at https:\/\/github.com\/azampvd\/DrugDiseaseNet.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Supplementary information<\/jats:title>\n                    <jats:p>Supplementary data are available at Bioinformatics online.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bioinformatics\/bty133","type":"journal-article","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T15:11:31Z","timestamp":1520521891000},"page":"2817-2825","source":"Crossref","is-referenced-by-count":108,"title":["A novel computational approach for drug repurposing using systems biology"],"prefix":"10.1093","volume":"34","author":[{"given":"Azam","family":"Peyvandipour","sequence":"first","affiliation":[{"name":"Computer Science, Wayne State University, Detroit, MI, USA"}]},{"given":"Nafiseh","family":"Saberian","sequence":"additional","affiliation":[{"name":"Computer Science, Wayne State University, Detroit, MI, USA"}]},{"given":"Adib","family":"Shafi","sequence":"additional","affiliation":[{"name":"Computer Science, Wayne State University, Detroit, MI, USA"}]},{"given":"Michele","family":"Donato","sequence":"additional","affiliation":[{"name":"Computer Science, Wayne State University, Detroit, MI, USA"}]},{"given":"Sorin","family":"Draghici","sequence":"additional","affiliation":[{"name":"Computer Science, Wayne State University, Detroit, MI, USA"},{"name":"Department of Obstetrics and Gynecology, Wayne State University, Detroit, MI, USA"}]}],"member":"286","published-online":{"date-parts":[[2018,3,9]]},"reference":[{"key":"2023012712593739500_bty133-B1","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1084\/jem.20041393","article-title":"Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis","volume":"201","author":"Abdollahi","year":"2005","journal-title":"J. Experimental Med"},{"key":"2023012712593739500_bty133-B2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0304-3835(02)00348-8","article-title":"Expression and activity of potassium ion channels in human prostate cancer","volume":"186","author":"Abdul","year":"2002","journal-title":"Cancer Lett"},{"key":"2023012712593739500_bty133-B3","first-page":"261","article-title":"Current and novel drug therapies for idiopathic pulmonary fibrosis","volume":"6","author":"Adamali","year":"2012","journal-title":"Drug Design Dev. Therapy"},{"key":"2023012712593739500_bty133-B4","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1377\/hlthaff.25.2.420","article-title":"Estimating the cost of new drug development: is it really $802 million?","volume":"25","author":"Adams","year":"2006","journal-title":"Health Affairs"},{"key":"2023012712593739500_bty133-B5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1476-4598-5-8","article-title":"Histone deacetylase inhibitor, trichostatin a induces ubiquitin-dependent cyclin d1 degradation in mcf-7 breast cancer cells","volume":"5","author":"Alao","year":"2006","journal-title":"Mol. Cancer"},{"key":"2023012712593739500_bty133-B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/rr162","article-title":"Growth factors in mocetinostat pulmonary fibrosis: relative roles","volume":"3","author":"Allen","year":"2001","journal-title":"Respiratory Res"},{"key":"2023012712593739500_bty133-B7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3816\/CGC.2008.n.015","article-title":"Pilot study of rapamycin in patients with hormone-refractory prostate cancer","volume":"6","author":"Amato","year":"2008","journal-title":"Clin. Genitourinary Cancer"},{"key":"2023012712593739500_bty133-B8","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1172\/JCI114808","article-title":"Platelet-derived growth factor in mocetinostat pulmonary fibrosis","volume":"86","author":"Antoniades","year":"1990","journal-title":"J. Clin. Investig"},{"key":"2023012712593739500_bty133-B9","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discovery"},{"key":"2023012712593739500_bty133-B10","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/1097-0142(19951215)76:12<2485::AID-CNCR2820761212>3.0.CO;2-J","article-title":"Phase II study of oral etoposide for patients with advanced breast cancer","volume":"76","author":"Atienza","year":"1995","journal-title":"Cancer"},{"key":"2023012712593739500_bty133-B11","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1214\/aos\/1013699998","article-title":"The control of the false discovery rate in multiple testing under dependency","volume":"29","author":"Benjamini","year":"2001","journal-title":"Ann Stat"},{"key":"2023012712593739500_bty133-B12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2174\/1871520614666140608150448","article-title":"Deoxypodophyllotoxin isolated from juniperus communis induces apoptosis in breast cancer cells","volume":"15","author":"Benzina","year":"2015","journal-title":"Anti-Cancer Agents Med. Chem. (Formerly Current Medicinal Chemistry-anti-Cancer Agents)"},{"key":"2023012712593739500_bty133-B13","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.bbadis.2012.06.008","article-title":"Tyrosine kinase signaling in fibrotic disorders: translation","volume":"1832","author":"Beyer","year":"2013","journal-title":"of basic research to human disease. Biochimica Et Biophysica Acta (BBA)-Mol. Basis Dis"},{"key":"2023012712593739500_bty133-B14","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1038\/srep02530","article-title":"Identification of FDA-approved drugs targeting breast cancer stem cells along with biomarkers of sensitivity","volume":"3","author":"Bhat-Nakshatri","year":"2013","journal-title":"Sci. Rep"},{"key":"2023012712593739500_bty133-B16","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1158\/1078-0432.CCR-0629-3","article-title":"Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer","volume":"10","author":"Boffa","year":"2004","journal-title":"Clin. Cancer Res"},{"key":"2023012712593739500_bty133-B17","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nrd1384","article-title":"Prospects for productivity","volume":"3","author":"Booth","year":"2004","journal-title":"Nat. Rev. Drug Discovery"},{"key":"2023012712593739500_bty133-B18","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1002\/cncr.24597","article-title":"Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (national cancer institute trial 6862)","volume":"115","author":"Bradley","year":"2009","journal-title":"Cancer"},{"key":"2023012712593739500_bty133-B19","first-page":"635","article-title":"Phase I\/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer","volume":"4","author":"Budd","year":"1998","journal-title":"Clin. Cancer Res"},{"key":"2023012712593739500_bty133-B20","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/nbt1017","article-title":"Systems biology in drug discovery","volume":"22","author":"Butcher","year":"2004","journal-title":"Nat. Biotechnol"},{"key":"2023012712593739500_bty133-B21","first-page":"249","article-title":"Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (hcc)","volume":"31","author":"Cainap","year":"2013","journal-title":"ASCO Annual Meeting Proc"},{"key":"2023012712593739500_bty133-B22","first-page":"776","article-title":"The potential role of PDGF, IGF-1, TGF-beta expression in mocetinostat pulmonary fibrosis","volume":"113","author":"Cao","year":"2000","journal-title":"Chin. Med. J"},{"key":"2023012712593739500_bty133-B23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12885-016-2188-2","article-title":"I\u03bab\u03b1 mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor","volume":"16","author":"Carter","year":"2016","journal-title":"BMC Cancer"},{"key":"2023012712593739500_bty133-B24","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1111\/j.1600-6143.2008.02430.x","article-title":"The effect of sirolimus on prostate-specific antigen (psa) levels in male renal transplant recipients without prostate cancer","volume":"8","author":"Chamie","year":"2008","journal-title":"Am. J. Transplantation"},{"key":"2023012712593739500_bty133-B25","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1200\/JCO.2012.45.8240","article-title":"RET fusion genes in non\u2013small-cell lung cancer","volume":"30","author":"Chao","year":"2012","journal-title":"J. Clin. Oncol"},{"key":"2023012712593739500_bty133-B26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3324\/haematol.2012.066407","article-title":"Ponatinib as targeted therapy for fgfr1 fusions associated with the 8p11 myeloproliferative syndrome","volume":"98","author":"Chase","year":"2013","journal-title":"Haematologica"},{"key":"2023012712593739500_bty133-B27","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1183\/09031936.00152106","article-title":"Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis","volume":"29","author":"Chaudhary","year":"2007","journal-title":"Eur. Respiratory J"},{"key":"2023012712593739500_bty133-B28","article-title":"Linifanib (ABT-869) potentiates the efficacy of chemotherapeutic agents through the suppression of receptor tyrosine kinase- mediated akt\/mtor signaling pathways in gastric cancer","volume":"6","author":"Chen","year":"2016","journal-title":"Sci. Rep"},{"key":"2023012712593739500_bty133-B29","doi-asserted-by":"crossref","first-page":"e62082","DOI":"10.1371\/journal.pone.0062082","article-title":"A synthetic podophyllotoxin derivative exerts anti-cancer effects by inducing mitotic arrest and pro-apoptotic ER stress in lung cancer preclinical models","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS One"},{"key":"2023012712593739500_bty133-B30","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.clinthera.2013.09.002","article-title":"Exposure-response (safety) analysis to identify linifanib dose for a phase III study in patients with hepatocellular carcinoma","volume":"35","author":"Chiu","year":"2013","journal-title":"Clin. Therapeutics"},{"key":"2023012712593739500_bty133-B31","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1200\/JCO.2011.41.0308","article-title":"Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy","volume":"30","author":"Choe","year":"2012","journal-title":"J. Clin. Oncol"},{"key":"2023012712593739500_bty133-B32","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.3892\/ijo.2015.3123","article-title":"Podophyllotoxin acetate triggers anticancer effects against non-small cell lung cancer cells by promoting cell death via cell cycle arrest, ER stress and autophagy","volume":"47","author":"Choi","year":"2015","journal-title":"Int. J. Oncol"},{"key":"2023012712593739500_bty133-B33","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/448645a","article-title":"New uses for old drugs","volume":"448","author":"Chong","year":"2007","journal-title":"Nature"},{"key":"2023012712593739500_bty133-B34","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrd3461","article-title":"Mining for therapeutic gold","volume":"10","author":"Collins","year":"2011","journal-title":"Nat. Rev. Drug Discovery"},{"key":"2023012712593739500_bty133-B35","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/labinvest.2013.6","article-title":"Pi3k p110\u03b3 overexpression in mocetinostat pulmonary fibrosis lung tissue and fibroblast cells: in vitro effects of its inhibition","volume":"93","author":"Conte","year":"2013","journal-title":"Laboratory Investig"},{"key":"2023012712593739500_bty133-B36","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"2023012712593739500_bty133-B37","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1365-2125.2010.03766.x","article-title":"Recent developments in prostate cancer biomarker research: therapeutic implications","volume":"71","author":"Detchokul","year":"2011","journal-title":"Br. J. Clin. Pharmacol"},{"key":"2023012712593739500_bty133-B38","first-page":"172","article-title":"The cost of new drug discovery and development","volume":"4","author":"Dickson","year":"2009","journal-title":"Discovery Med"},{"key":"2023012712593739500_bty133-B39","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0167-6296(02)00126-1","article-title":"The price of innovation: new estimates of drug development costs","volume":"22","author":"DiMasi","year":"2003","journal-title":"J. Health Econ"},{"key":"2023012712593739500_bty133-B40","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1101\/gr.6202607","article-title":"A systems biology approach for pathway level analysis","volume":"17","author":"Dr\u01ceghici","year":"2007","journal-title":"Genome Res"},{"key":"2023012712593739500_bty133-B41","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/bib\/bbr013","article-title":"Exploiting drug\u2013disease relationships for computational drug repositioning","volume":"12","author":"Dudley","year":"2011","journal-title":"Brief. Bioinform"},{"key":"2023012712593739500_bty133-B42","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/nar\/30.1.207","article-title":"Gene Expression Omnibus: nCBI gene expression and hybridization array data repository","volume":"30","author":"Edgar","year":"2002","journal-title":"Nucleic Acids Res"},{"key":"2023012712593739500_bty133-B43","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/JTO.0b013e31825581bd","article-title":"The mTOR pathway in lung cancer and implications for therapy and biomarker analysis","volume":"7","author":"Ekman","year":"2012","journal-title":"J.Thoracic Oncol"},{"key":"2023012712593739500_bty133-B44","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1634\/theoncologist.2013-0095","article-title":"Novel targets in non-small cell lung cancer: rOS1 and RET fusions","volume":"18","author":"Gainor","year":"2013","journal-title":"Oncologist"},{"key":"2023012712593739500_bty133-B45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/bcr3245","article-title":"Retinoids and breast cancer: new clues to increase their activity and selectivity","volume":"14","author":"Garattini","year":"2012","journal-title":"Breast Cancer Res"},{"key":"2023012712593739500_bty133-B46","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/bioinformatics\/btg405","article-title":"affy\u2013analysis of Affymetrix GeneChip data at the probe level","volume":"20","author":"Gautier","year":"2004","journal-title":"Bioinformatics"},{"key":"2023012712593739500_bty133-B47","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1200\/JCO.2016.70.9352","article-title":"Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry","volume":"35","author":"Gautschi","year":"2017","journal-title":"J. Clin. Oncol"},{"key":"2023012712593739500_bty133-B48","first-page":"473","article-title":"Chloroquine-induced autophagic vacuole accumulation and cell death in glioma cells is p53 independent","volume":"12","author":"Geng","year":"2010","journal-title":"Neuro-Oncology"},{"key":"2023012712593739500_bty133-B49","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","article-title":"Strategies for subtypes\u2013dealing with the diversity of breast cancer: highlights of the st gallen international expert consensus on the primary therapy of early breast cancer 2011","volume":"22","author":"Goldhirsch","year":"2011","journal-title":"Ann. Oncol"},{"key":"2023012712593739500_bty133-B50","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.2174\/1381612003398582","article-title":"Antitumor properties of podophyllotoxin and related compounds","volume":"6","author":"Gordaliza","year":"2000","journal-title":"Curr. Pharmaceutical Design"},{"key":"2023012712593739500_bty133-B51","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1046\/j.1442-2042.1999.00069.x","article-title":"The effect of papaverine on morphologic differentiation, proliferation and invasive potential of human prostatic cancer lncap cells","volume":"6","author":"Goto","year":"1999","journal-title":"Int. J. Urol"},{"key":"2023012712593739500_bty133-B52","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1634\/theoncologist.2007-0171","article-title":"The potential role of mTOR inhibitors in non-small cell lung cancer","volume":"13","author":"Gridelli","year":"2008","journal-title":"Oncologist"},{"key":"2023012712593739500_bty133-B53","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/nrd3297","article-title":"Targeting non-malignant disorders with tyrosine kinase inhibitors","volume":"9","author":"Grimminger","year":"2010","journal-title":"Nat. Rev. Drug Discovery"},{"key":"2023012712593739500_bty133-B54","article-title":"The role of tyrosine kinases in the pathogenesis of mocetinostat pulmonary fibrosis","volume":"51","author":"Grimminger","year":"2015","journal-title":"Eur. Respir. J"},{"key":"2023012712593739500_bty133-B55","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.clbc.2011.03.021","article-title":"Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer","volume":"11","author":"Gucalp","year":"2011","journal-title":"Clin. Breast Cancer"},{"key":"2023012712593739500_bty133-B56","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1023\/A:1015788502099","article-title":"Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the us","volume":"13","author":"Habel","year":"2002","journal-title":"Cancer Causes Control"},{"key":"2023012712593739500_bty133-B57","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1164\/ajrccm.152.6.8520779","article-title":"Localization of platelet-derived growth factor and insulin-like growth factor I in the fibrotic lung","volume":"152","author":"Homma","year":"1995","journal-title":"Am. J. Respiratory Crit. Care Med"},{"key":"2023012712593739500_bty133-B58","doi-asserted-by":"crossref","first-page":"14272","DOI":"10.1038\/s41598-017-14612-5","article-title":"Involvement of ER stress, PI3K\/AKT activation, and lung fibroblast proliferation in bleomycin-induced pulmonary fibrosis","volume":"7","author":"Hsu","year":"2017","journal-title":"Sci. Rep"},{"key":"2023012712593739500_bty133-B59","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1124\/jpet.114.216044","article-title":"Therapeutic targeting of SRC kinase in myofibroblast differentiation and pulmonary fibrosis","volume":"351","author":"Hu","year":"2014","journal-title":"J. Pharmacol. Experimental Therapeutics"},{"key":"2023012712593739500_bty133-B60","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.3892\/ol.2016.4943","article-title":"Anticancer effect of deoxypodophyllotoxin induces apoptosis of human prostate cancer cells","volume":"12","author":"Hu","year":"2016","journal-title":"Oncol. Lett"},{"key":"2023012712593739500_bty133-B61","first-page":"112","article-title":"Papaverine selectively inhibits human prostate cancer cell (PC-3) growth by inducing mitochondrial mediated apoptosis, cell cycle arrest and downregulation of nf-\u03bab\/pi3k\/akt signalling pathway","volume":"22","author":"Huang","year":"2017","journal-title":"J. BU oN Off. J. Balkan Union Oncol"},{"key":"2023012712593739500_bty133-B62","first-page":"1772","article-title":"Rapamycin inhibits prostate cancer cell growth through cyclin D1 and enhances the cytotoxic efficacy of cisplatin","volume":"6","author":"Imrali","year":"2016","journal-title":"Am. J. Cancer Res"},{"key":"2023012712593739500_bty133-B63","doi-asserted-by":"crossref","first-page":"L727","DOI":"10.1152\/ajplung.00209.2003","article-title":"Induction of CDK inhibitor p21 gene as a new therapeutic strategy against pulmonary fibrosis","volume":"286","author":"Inoshima","year":"2004","journal-title":"Am. J. Physiol.-Lung Cell. Mol. Physiol"},{"key":"2023012712593739500_bty133-B64","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/jnci\/dji173","article-title":"A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence","volume":"97","author":"Jacobs","year":"2005","journal-title":"J. Natl. Cancer Inst"},{"key":"2023012712593739500_bty133-B65","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1038\/sj.onc.1207315","article-title":"The histone deacetylase inhibitor trichostatin a sensitizes estrogen receptor \u03b1-negative breast cancer cells to tamoxifen","volume":"23","author":"Jang","year":"2004","journal-title":"Oncogene"},{"key":"2023012712593739500_bty133-B66","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.3892\/ol.2017.6032","article-title":"Synergistic activity of the histone deacetylase inhibitor trichostatin a and the proteasome inhibitor ps-341 against taxane-resistant ovarian cancer cell lines","volume":"13","author":"Jin","year":"2017","journal-title":"Oncol. Lett"},{"key":"2023012712593739500_bty133-B67","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/sj.bjc.6601897","article-title":"Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer","volume":"91","author":"Jones","year":"2004","journal-title":"Br. J. Cancer"},{"key":"2023012712593739500_bty133-B68","doi-asserted-by":"crossref","first-page":"24020","DOI":"10.1074\/jbc.M113.473819","article-title":"Interaction of glucocorticoid receptor (GR) with estrogen receptor (er) \u03b1 and activator protein 1 (AP1) in dexamethasone-mediated interference of ER\u03b1 activity","volume":"288","author":"Karmakar","year":"2013","journal-title":"J. Biol. Chem"},{"key":"2023012712593739500_bty133-B69","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.arcmed.2012.04.005","article-title":"Matrix metalloproteinase-2 and-9 in glioblastoma: a trio of old drugs\u2013captopril, disulfiram and nelfinavir\u2013are inhibitors with potential as adjunctive treatments in glioblastoma","volume":"43","author":"Kast","year":"2012","journal-title":"Arch. Med. Res"},{"key":"2023012712593739500_bty133-B70","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/1756287215597637","article-title":"Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials","volume":"7","author":"Kaushik","year":"2015","journal-title":"Therapeutic Adv. Urol"},{"key":"2023012712593739500_bty133-B71","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1471-2407-8-84","article-title":"Systematic review of the clinical effect of glucocorticoids on nonhematologic malignancy","volume":"8","author":"Keith","year":"2008","journal-title":"BMC Cancer"},{"key":"2023012712593739500_bty133-B72","first-page":"166","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs","volume":"3","author":"Kim","year":"2011","journal-title":"Am. J. Trans. Res"},{"key":"2023012712593739500_bty133-B73","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/jcb.24455","article-title":"Interplay of reactive oxygen species, intracellular ca2+ and mitochondrial homeostasis in the apoptosis of prostate cancer cells by deoxypodophyllotoxin","volume":"114","author":"Kim","year":"2013","journal-title":"J. Cell. Biochem"},{"key":"2023012712593739500_bty133-B74","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1126\/science.1069492","article-title":"Systems biology: a brief overview","volume":"295","author":"Kitano","year":"2002","journal-title":"Science"},{"key":"2023012712593739500_bty133-B75","doi-asserted-by":"crossref","first-page":"P38","DOI":"10.1186\/1476-9255-10-S1-P38","article-title":"Therapeutic efficacy of Sunitinib and other broad spectrum receptor tyrosine kinase inhibitors (RTKI) in bleomycin-induced pulmonary fibrosis","volume":"10","author":"Knoerzer","year":"2013","journal-title":"J. Inflammation"},{"key":"2023012712593739500_bty133-B76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/454783","article-title":"Synergistic inhibition of angiogenesis by artesunate and captopril in vitro and in vivo","volume":"2013","author":"Krusche","year":"2013","journal-title":"Evidence-Based Complementary Alternative Med"},{"key":"2023012712593739500_bty133-B77","doi-asserted-by":"crossref","first-page":"e1570","DOI":"10.1097\/MD.0000000000001570","article-title":"Colchicine significantly reduces incident cancer in gout male patients: a 12-year cohort study","volume":"94","author":"Kuo","year":"2015","journal-title":"Medicine"},{"key":"2023012712593739500_bty133-B78","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1126\/science.1132939","article-title":"The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease","volume":"313","author":"Lamb","year":"2006","journal-title":"Science"},{"key":"2023012712593739500_bty133-B79","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1200\/JCO.2009.22.1291","article-title":"Histone deacetylase inhibitors in cancer therapy","volume":"27","author":"Lane","year":"2009","journal-title":"J. Clin. Oncol"},{"key":"2023012712593739500_bty133-B80","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/CAD.0b013e328325a867","article-title":"A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a california cancer consortium study","volume":"20","author":"Lara","year":"2009","journal-title":"Anti-Cancer Drugs"},{"key":"2023012712593739500_bty133-B81","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/j.1476-5381.2009.00402.x","article-title":"Cyclin-dependent kinase inhibitor drugs as potential novel anti-inflammatory and pro-resolution agents","volume":"158","author":"Leitch","year":"2009","journal-title":"Br. J. Pharmacol"},{"key":"2023012712593739500_bty133-B82","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.steroids.2016.02.019","article-title":"New dimension of glucocorticoids in cancer treatment","volume":"111","author":"Lin","year":"2016","journal-title":"Steroids"},{"key":"2023012712593739500_bty133-B83","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.kjms.2015.12.006","article-title":"Anticancer effects of clinically acceptable colchicine concentrations on human gastric cancer cell lines","volume":"32","author":"Lin","year":"2016","journal-title":"Kaohsiung J. Med. Sci"},{"key":"2023012712593739500_bty133-B84","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1038\/sj.onc.1208661","article-title":"Expression of estrogen receptor \u03b1, retinoic acid receptor \u03b1 and cellular retinoic acid binding protein II genes is coordinately regulated in human breast cancer cells","volume":"24","author":"Lu","year":"2005","journal-title":"Oncogene"},{"key":"2023012712593739500_bty133-B85","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.canlet.2015.11.044","article-title":"Deoxypodophyllotoxin triggers parthanatos in glioma cells via induction of excessive ROS","volume":"371","author":"Ma","year":"2016","journal-title":"Cancer Lett"},{"key":"2023012712593739500_bty133-B86","first-page":"1","article-title":"Maintenance use of aspirin or other non-steroidal anti-inflammatory drugs (nsaids) and prostate cancer risk","author":"Ma","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2023012712593739500_bty133-B87","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1165\/rcmb.2011-0237OC","article-title":"MEK-ERK pathway modulation ameliorates pulmonary fibrosis associated with epidermal growth factor receptor activation","volume":"46","author":"Madala","year":"2012","journal-title":"Am. J. Respiratory Cell Mol. Biol"},{"key":"2023012712593739500_bty133-B88","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1158\/0008-5472.CAN-12-2633","article-title":"Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer","volume":"73","author":"Maire","year":"2013","journal-title":"Cancer Res"},{"key":"2023012712593739500_bty133-B89","doi-asserted-by":"crossref","first-page":"e63712","DOI":"10.1371\/journal.pone.0063712","article-title":"TTK\/hMPS1 is an attractive therapeutic target for triple-negative breast cancer","volume":"8","author":"Maire","year":"2013","journal-title":"PloS One"},{"key":"2023012712593739500_bty133-B90","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/jez.a.307","article-title":"The comparative toxicogenomics database (CTD): a resource for comparative toxicological studies","volume":"305A","author":"Mattingly","year":"2006","journal-title":"J. Experimental Zool. Part A: Comparative Experimental Biol"},{"key":"2023012712593739500_bty133-B91","doi-asserted-by":"crossref","first-page":"e0122333","DOI":"10.1371\/journal.pone.0122333","article-title":"Transcriptome analysis of Wnt3a-treated triple-negative breast cancer cells","volume":"10","author":"Maubant","year":"2015","journal-title":"PloS One"},{"key":"2023012712593739500_bty133-B92","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1093\/nar\/gnh071","article-title":"Sequence-matched probes produce increased cross-platform consistency and more reproducible biological results in microarray-based gene expression measurements","volume":"32","author":"Mecham","year":"2004","journal-title":"Nucleic Acids Res"},{"key":"2023012712593739500_bty133-B93","doi-asserted-by":"crossref","DOI":"10.1136\/thoraxjnl-2015-207429","article-title":"Exploration of a potent PI3 kinase\/mTOR inhibitor as a novel anti-fibrotic agent in IPF","author":"Mercer","year":"2016","journal-title":"Thorax"},{"key":"2023012712593739500_bty133-B94","first-page":"e14515","article-title":"A phase II trial of saracatinib (AZD0530), an oral src inhibitor, in previously treated metastatic pancreatic cancer","volume":"28","author":"Messersmith","year":"2010","journal-title":"ASCO Ann Meeting Proc"},{"key":"2023012712593739500_bty133-B95","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.3390\/molecules20033898","article-title":"Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents","volume":"20","author":"Mottamal","year":"2015","journal-title":"Molecules"},{"key":"2023012712593739500_bty133-B96","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N. Engl. J. Med"},{"key":"2023012712593739500_bty133-B97","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.biopha.2014.05.004","article-title":"The role of captopril and losartan in prevention and regression of tamoxifen-induced resistance of breast cancer cell line MCF-7: an in vitro study","volume":"68","author":"Namazi","year":"2014","journal-title":"Biomed. Pharmacotherapy"},{"key":"2023012712593739500_bty133-B98","first-page":"169","article-title":"Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study","volume":"7","author":"Nelson","year":"2000","journal-title":"Oncol. Rep"},{"key":"2023012712593739500_bty133-B99","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1097\/JTO.0b013e318219a973","article-title":"Phase II study of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases","volume":"6","author":"Novello","year":"2011","journal-title":"J. Thoracic Oncol"},{"key":"2023012712593739500_bty133-B100","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/2050-6511-14-6","article-title":"Glibenclamide inhibits cell growth by inducing g0\/g1 arrest in the human breast cancer cell line mda-mb-231","volume":"14","author":"N\u00fa\u00f1ez","year":"2013","journal-title":"BMC Pharmacol. Toxicol"},{"key":"2023012712593739500_bty133-B101","first-page":"1","article-title":"A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer\u2019s disease","volume":"7","author":"Nygaard","year":"2015","journal-title":"Alzheimer\u2019s Res. Therapy"},{"key":"2023012712593739500_bty133-B102","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1165\/rcmb.2013-0092OC","article-title":"Inhibition of transglutaminase 2, a novel target for pulmonary fibrosis, by two small electrophilic molecules","volume":"50","author":"Olsen","year":"2014","journal-title":"Am. J. Respiratory Cell Mol. Biol"},{"key":"2023012712593739500_bty133-B103","article-title":"DrugVsDisease: comparison of disease and drug profiles using Gene set Enrichment Analysis","author":"Pacini","year":"2013","journal-title":"Bioinformatics"},{"key":"2023012712593739500_bty133-B104","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1038\/onc.2011.506","article-title":"Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with coamplification of ERBB2 and RARA","volume":"31","author":"Paroni","year":"2012","journal-title":"Oncogene"},{"key":"2023012712593739500_bty133-B105","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/sj.bjp.0703863","article-title":"The sulphonylurea glibenclamide inhibits multidrug resistance protein (mrp1) activity in human lung cancer cells","volume":"132","author":"Payen","year":"2001","journal-title":"Br. J. Pharmacol"},{"key":"2023012712593739500_bty133-B106","first-page":"304","article-title":"A randomized phase II clinical trial of the src inhibitor saracatinib (AZD0530) and carboplatin plus paclitaxel (C plus P) versus C plus p in patients (PTS) wiht advanced platinum-sensitive epithelial ovarian cancer (EOC)","volume":"21 (Suppl. 8)","author":"Poole","year":"2010","journal-title":"Ann. Oncol"},{"key":"2023012712593739500_bty133-B107","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1097\/JTO.0b013e3181ec1531","article-title":"Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer","volume":"5","author":"Price","year":"2010","journal-title":"J. Thoracic Oncol"},{"key":"2023012712593739500_bty133-B108","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.bcp.2008.09.009","article-title":"Glibenclamide exerts an antitumor activity through reactive oxygen species\u2013c-jun nh (2)-terminal kinase pathway in human gastric cancer cell line mgc-803","volume":"76","author":"Qian","year":"2008","journal-title":"Biochem. Pharmacol"},{"key":"2023012712593739500_bty133-B110","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.3892\/or.2013.2386","article-title":"Novel fgfr inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing fgfr1","volume":"29","author":"Ren","year":"2013","journal-title":"Oncol. Rep"},{"key":"2023012712593739500_bty133-B111","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000327719","article-title":"Effect of nilotinib on bleomycin-induced acute lung injury and pulmonary fibrosis in mice","volume":"82","author":"Rhee","year":"2011","journal-title":"Respiration"},{"key":"2023012712593739500_bty133-B112","first-page":"10","article-title":"The histone deacetylase inhibitor trichostatin a alters microrna expression profiles in apoptosis-resistant breast cancer cells","volume":"27","author":"Rhodes","year":"2012","journal-title":"Oncol. Rep"},{"key":"2023012712593739500_bty133-B113","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","article-title":"Efficacy of a tyrosine kinase inhibitor in mocetinostat pulmonary fibrosis","volume":"365","author":"Richeldi","year":"2011","journal-title":"N. Engl. J. Med"},{"key":"2023012712593739500_bty133-B114","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1023\/B:APPT.0000038037.68908.6e","article-title":"Mechanism of histone deacetylase inhibitor trichostatin a induced apoptosis in human osteosarcoma cells","volume":"9","author":"Roh","year":"2004","journal-title":"Apoptosis"},{"key":"2023012712593739500_bty133-B115","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1756-9966-32-32","article-title":"Combined treatment of glibenclamide and cocl2 decreases mmp9 expression and inhibits growth in highly metastatic breast cancer","volume":"32","author":"Rong","year":"2013","journal-title":"J. Experimental Clin. Cancer Res"},{"key":"2023012712593739500_bty133-B116","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.0305-1846.2000.00298.x","article-title":"Evaluation of the effects of swainsonine, captopril, tangeretin and nobiletin on the biological behaviour of brain tumour cells in vitro","volume":"27","author":"Rooprai","year":"2001","journal-title":"Neuropathol. Appl. Neurobiol"},{"key":"2023012712593739500_bty133-B117","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(10)62110-1","article-title":"Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials","volume":"377","author":"Rothwell","year":"2011","journal-title":"Lancet"},{"key":"2023012712593739500_bty133-B118","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/bcp.12785","article-title":"Repurposing some older drugs that cross the blood\u2013brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma","volume":"81","author":"Rundle-Thiele","year":"2016","journal-title":"Br. J. Clin. Pharmacol"},{"key":"2023012712593739500_bty133-B119","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1097\/JTO.0b013e3180cc2587","article-title":"Phase i trial of sirolimus combined with radiation and cisplatin in non-small cell lung cancer","volume":"2","author":"Sarkaria","year":"2007","journal-title":"J. Thoracic Oncol"},{"key":"2023012712593739500_bty133-B120","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1517\/13543780903485642","article-title":"Targeting cancer with phosphodiesterase inhibitors","volume":"19","author":"Savai","year":"2010","journal-title":"Expert Opin. Investigational Drugs"},{"key":"2023012712593739500_bty133-B121","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.canlet.2012.07.029","article-title":"Inhibition of autophagy and induction of breast cancer cell death by mefloquine, an antimalarial agent","volume":"326","author":"Sharma","year":"2012","journal-title":"Cancer Lett"},{"key":"2023012712593739500_bty133-B122","doi-asserted-by":"crossref","first-page":"96ra77","DOI":"10.1126\/scitranslmed.3001318","article-title":"Discovery and preclinical validation of drug indications using compendia of public gene expression data","volume":"3","author":"Sirota","year":"2011","journal-title":"Sci. Trans. Med"},{"key":"2023012712593739500_bty133-B123","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s10552-016-0785-7","article-title":"Low-dose aspirin or other nonsteroidal anti-inflammatory drug use and prostate cancer risk: a nationwide study","volume":"27","author":"Skriver","year":"2016","journal-title":"Cancer Causes Control"},{"key":"2023012712593739500_bty133-B124","first-page":"397","article-title":"Limma: linear models for microarray data","author":"Smyth","year":"2005"},{"key":"2023012712593739500_bty133-B125","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1200\/jco.2006.24.18_suppl.7001","article-title":"Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (nsclc): preliminary results of a multicenter phase ii trial","volume":"24 (Suppl 18)","author":"Socinski","year":"2006","journal-title":"J. Clin. Oncol"},{"key":"2023012712593739500_bty133-B126","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1093\/annonc\/mdp060","article-title":"Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors","volume":"20","author":"Soria","year":"2009","journal-title":"Ann. Oncol"},{"key":"2023012712593739500_bty133-B127","first-page":"570","article-title":"Proliferation inhibition and apoptosis of breast cancer mcf-7 cells under the influence of colchicine","volume":"3","author":"Sun","year":"2016","journal-title":"J. Buon"},{"key":"2023012712593739500_bty133-B128","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s002800050666","article-title":"Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase ii trial","volume":"40","author":"Sutton","year":"1997","journal-title":"Cancer Chemotherapy Pharmacol"},{"key":"2023012712593739500_bty133-B129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2010\/923824","article-title":"Preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancer","volume":"2010","author":"Takai","year":"2010","journal-title":"Obstetrics Gynecol. Int"},{"key":"2023012712593739500_bty133-B130","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nrclinonc.2015.90","article-title":"Refining the treatment of NSCLC according to histological and molecular subtypes","volume":"12","author":"Thomas","year":"2015","journal-title":"Nat. Rev. Clin. Oncol"},{"key":"2023012712593739500_bty133-B131","first-page":"971","article-title":"Trichostatin a is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo","volume":"7","author":"Vigushin","year":"2001","journal-title":"Clin. Cancer Res"},{"key":"2023012712593739500_bty133-B132","volume-title":"ROntoTools: R Onto-Tools Suite","author":"Voichi\u0163a","year":"2013"},{"key":"2023012712593739500_bty133-B133","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1158\/0008-5472.CAN-13-2133","article-title":"Global gene repression by the steroid receptor coactivator SRC-1 promotes oncogenesis","volume":"74","author":"Walsh","year":"2014","journal-title":"Cancer Res"},{"key":"2023012712593739500_bty133-B134","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.3109\/10428194.2012.660631","article-title":"Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia","volume":"53","author":"Wang","year":"2012","journal-title":"Leukemia Lymphoma"},{"key":"2023012712593739500_bty133-B135","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1423-0127-18-44","article-title":"Specific microtubule-depolymerizing agents augment efficacy of dendritic cell-based cancer vaccines","volume":"18","author":"Wen","year":"2011","journal-title":"J. Biomed. Sci"},{"key":"2023012712593739500_bty133-B136","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2307\/3001968","article-title":"Individual comparisons by ranking methods","volume":"1","author":"Wilcoxon","year":"1945","journal-title":"Biometrics"},{"key":"2023012712593739500_bty133-B137","doi-asserted-by":"crossref","first-page":"D668","DOI":"10.1093\/nar\/gkj067","article-title":"DrugBank: a comprehensive resource for in silico drug discovery and exploration","volume":"34","author":"Wishart","year":"2006","journal-title":"Nucleic Acids Res"},{"key":"2023012712593739500_bty133-B138","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1124\/jpet.113.208223","article-title":"Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis","volume":"349","author":"Wollin","year":"2014","journal-title":"J. Pharmacol. Experimental Therapeutics"},{"key":"2023012712593739500_bty133-B139","article-title":"Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis","volume":"51","author":"Wollin","year":"2015","journal-title":"Eur. Respiratory J"},{"key":"2023012712593739500_bty133-B141","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/mc.21875","article-title":"Curcumin enhances the anticancer effects of trichostatin a in breast cancer cells","volume":"52","author":"Yan","year":"2013","journal-title":"Mol. Carcinogenesis"},{"key":"2023012712593739500_bty133-B142","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.3892\/ol.2013.1259","article-title":"Mefloquine induces cell death in prostate cancer cells and provides a potential novel treatment strategy in vivo","volume":"5","author":"Yan","year":"2013","journal-title":"Oncol. Lett"},{"key":"2023012712593739500_bty133-B143","first-page":"6890","article-title":"Transcriptional activation of estrogen receptor \u03b1 in human breast cancer cells by histone deacetylase inhibition","volume":"60","author":"Yang","year":"2000","journal-title":"Cancer Res"},{"key":"2023012712593739500_bty133-B144","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.febslet.2012.04.007","article-title":"Suppression of cellular invasion by glybenclamide through inhibited secretion of platelet-derived growth factor in ovarian clear cell carcinoma ES-2 cells","volume":"586","author":"Yasukagawa","year":"2012","journal-title":"FEBS Lett"},{"key":"2023012712593739500_bty133-B145","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/path.1208","article-title":"MAP kinase activation and apoptosis in lung tissues from patients with idiopathic pulmonary fibrosis","volume":"198","author":"Yoshida","year":"2002","journal-title":"J. Pathol"},{"key":"2023012712593739500_bty133-B146","first-page":"775","article-title":"Oral etoposide monotherapy is effective for metastatic breast cancer with heavy prior therapy","volume":"125","author":"Yuan","year":"2012","journal-title":"Chin. Med. J"},{"key":"2023012712593739500_bty133-B147","doi-asserted-by":"crossref","first-page":"e774","DOI":"10.1097\/MD.0000000000000774","article-title":"Efficacy of oral etoposide in pretreated metastatic breast cancer: a multicenter phase 2 study","volume":"94","author":"Yuan","year":"2015","journal-title":"Medicine"},{"key":"2023012712593739500_bty133-B148","doi-asserted-by":"crossref","first-page":"240ra76","DOI":"10.1126\/scitranslmed.3007096","article-title":"Chitinase 3\u2013like 1 suppresses injury and promotes fibroproliferative responses in mammalian lung fibrosis","volume":"6","author":"Zhou","year":"2014","journal-title":"Sci. Trans. Med"}],"container-title":["Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bioinformatics\/article-pdf\/34\/16\/2817\/48917959\/bioinformatics_34_16_2817.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bioinformatics\/article-pdf\/34\/16\/2817\/48917959\/bioinformatics_34_16_2817.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T17:58:35Z","timestamp":1719856715000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bioinformatics\/article\/34\/16\/2817\/4925258"}},"subtitle":[],"editor":[{"given":"Alfonso","family":"Valencia","sequence":"additional","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2018,3,9]]},"references-count":145,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2018,8,15]]}},"URL":"https:\/\/doi.org\/10.1093\/bioinformatics\/bty133","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732830658.793546642","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.732830658.793550473","asserted-by":"object"}]},"ISSN":["1367-4803","1367-4811"],"issn-type":[{"value":"1367-4803","type":"print"},{"value":"1367-4811","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,8,15]]},"published":{"date-parts":[[2018,3,9]]}}}